Previous 10 | Next 10 |
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® PR Newswire SAN DIEGO , May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial-stage oncology co...
2023-05-20 04:46:48 ET Summary Mirati Therapeutics has achieved significant success with its FDA-approved cancer drug, Krazati, but the company's recent financials reveal potential challenges ahead. Despite earning $6.3M in product revenue from Krazati in Q1 2023, rising operation...
2023-05-09 22:44:09 ET Mirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Ryan Asay – Vice President-Corporate Affairs David Meek – Chief Executive Officer Ben Hickey – Chief Commerci...
2023-05-09 16:30:54 ET Mirati Therapeutics press release ( NASDAQ: MRTX ): Q1 GAAP EPS of -$3.18 beats by $0.41 . Revenue of $7.17M (+909.9% Y/Y) beats by $2.37M . Net reduction in cash, cash equivalents and short-term investments for the first quarter was $181...
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced fi...
2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies PR Newswire SAN DIEGO and NASHVILLE, Tenn. , May 8, 2023 /PRNewswire/ -- Mirati Therapeutics, I...
2023-04-27 18:01:59 ET Gainers: Mirati Therapeutics ( MRTX ) +10% . JAKKS Pacific ( JAKK ) +10% . Amazon.com ( AMZN ) +9% . Datadog ( DDOG ) +8% . Recursion Pharmaceuticals ( RXRX ) +6% . Losers: Accolade ( ACCD ) -...
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference PR Newswire SAN DIEGO , April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will partici...
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors PR Newswire Data demonstrates compelling clinical activity, highlights adagrasib potential as monothera...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...